ArticleNucleic acids research2026
CRISPR-mediated gap-based replacement enables site-specific DNA lesion insertion into long DNA and nucleosomes.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Defined DNA lesions are essential substrates for dissecting DNA repair mechanisms, yet existing approaches remain limited in positional flexibility, lesion diversity, efficiency, or compatibility with long and chromatinized DNA. Here, we present CGRID (CRISPR-mediated Gap-based Replacement for Insertion of DNA damage), a programmable strategy for site-specific installation of DNA lesions into long DNA and nucleosomes. CGRID uses paired Cas9 nickases to generate two adjacent nicks, followed by gap formation and replacement with a synthetic lesion-containing oligonucleotide. This design enables easy and efficient insertion of diverse DNA lesions at user-defined positions without pre-engineered nicking sites or substrate redesign. Applied to long λ-DNA, CGRID supports efficient installation of single lesions and internal double-strand breaks at predefined positions, which are challenging to obtain using existing methods. These molecules enable high-throughput single-molecule analysis of diverse repair pathways including base excision repair (BER), nonhomologous end joining, and microhomology-mediated end joining without hydrodynamic force. CGRID further allows efficient site-specific lesion incorporation into nucleosomal DNA, enabling systematic repositioning of damage within a nucleosome. This shows that nucleosome context and lesion orientation strongly influence APE1 incision efficiency. Together, CGRID establishes a broadly applicable platform for programmable DNA damage engineering, bridging biochemical and single-molecule methodologies, and facilitates mechanistic studies of chromatin-dependent genome maintenance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.